Literature DB >> 27165606

Structural valvular deterioration of Hancock standard valve in the mitral position 33 years after initial implantation.

Hiroyuki Saisho1, Keiichiro Tayama2, Koichiro Shimoishi2, Hidetsugu Hori2, Teiji Okazaki2.   

Abstract

A 77-year-old woman who had undergone mitral valve replacement (MVR) with a 29 mm Hancock standard (H-S) bioprosthesis (Model 242) and tricuspid annuloplasty (Kay's method) at the age of 44 years was admitted urgently with acute heart failure. Echocardiography showed severe transvalvular leakage of the prosthesis and moderate tricuspid regurgitation. The patient underwent reMVR with a 29 mm Carpentier-Edwards Perimount Magna Mitral bioprosthesis and tricuspid annuloplasty with a 30 mm MC3 ring. The explanted bioprosthesis showed mild calcification and a tear in the leaflet, dehisced commissures and pannus overgrowth. To our knowledge there are no reports describing H-S valves that were still functioning over 30 years after implantation. Herein, we report a case of reMVR in a patient with an H-S valve that had been implanted 33 years previously.

Entities:  

Keywords:  Evaluation of explanted valve; Hancock standard bioprosthesis; Mitral valve replacement; Structural valvular deterioration

Mesh:

Year:  2016        PMID: 27165606     DOI: 10.1007/s10047-016-0903-z

Source DB:  PubMed          Journal:  J Artif Organs        ISSN: 1434-7229            Impact factor:   1.731


  7 in total

Review 1.  The pathology of Hancock standard porcine valve prosthesis: a 20-year span of experience.

Authors:  M Valente; M Minarini; G Thiene; U Bortolotti; A Milano; E Talenti; V Gallucci
Journal:  J Card Surg       Date:  1990-12       Impact factor: 1.620

2.  Over twenty-year follow-up of the standard Hancock porcine bioprosthesis implanted in the mitral position.

Authors:  F Santini; G B Luciani; S Restivo; G Casali; R Pessotto; P Bertolini; A Rossi; A Mazzucco
Journal:  Ann Thorac Surg       Date:  2001-05       Impact factor: 4.330

Review 3.  Malfunction of a Hancock bioprosthesis in the mitral position 24 years after initial implantation.

Authors:  H Niinami; Y Naito; H Koyanagi; H Nagashima; H Kasanuki
Journal:  J Heart Valve Dis       Date:  2000-11

4.  Calcific degeneration of bioprosthetic aortic valves in patients receiving steroid therapy.

Authors:  K Eishi; H Ishibashi-Ueda; K Nakano; Y Kosakai; Y Sasako; J Kobayashi; C Yutani
Journal:  J Heart Valve Dis       Date:  1996-11

5.  Mitral valve re-replacement for impaired bioprosthesis after 19 years in a patient undergoing steroid treatment.

Authors:  Yasuhisa Shimazaki; Setsuo Kuraoka; Fumihiro Takeda; Takao Watanabe; Kiyoshige Inui
Journal:  J Heart Valve Dis       Date:  2003-01

6.  Transapical transcatheter valve-in-valve implantation for deteriorated mitral valve bioprostheses.

Authors:  Manuel Wilbring; Konstantin Alexiou; Sems Malte Tugtekin; Bjoern Sill; Peter Hammer; Torsten Schmidt; Gregor Simonis; Klaus Matschke; Utz Kappert
Journal:  Ann Thorac Surg       Date:  2012-10-11       Impact factor: 4.330

7.  Mechanical prosthesis is reasonable for mitral valve replacement in patients approximately 65 years of age.

Authors:  Takahiro Nishida; Hiromichi Sonoda; Yasuhisa Oishi; Yoshihisa Tanoue; Atsuhiro Nakashima; Yuichi Shiokawa; Ryuji Tominaga
Journal:  Ann Thorac Surg       Date:  2013-07-25       Impact factor: 4.330

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.